Research ArticleOpen AccessGoogle Scholar indexed

Non-Linear Mathematical Model of the Interaction between Tumor and Oncolytic Viruses

¹ Department of Mathematics, The Madura College, Madurai, India
² Department of Mathematics, The Madura College, Madurai, India
³ Department of Mathematics, V V College of Engineering, Tisaiyanvilai, India
⁴ Department of Mathematics, The Madura College, Madurai, India

Applied Mathematics·Volume 03 (2012)·Pages 1089–1096·Published 27 September 2012·DOI10.4236/am.2012.39160

Abstract

A mathematical modeling of tumor therapy with oncolytic viruses is discussed. The model consists of two coupled, deterministic differential equations allowing for cell reproduction and death, and cell infection. The model is one of the conceptual mathematical models of tumor growth that treat a tumor as a dynamic society of interacting cells. In this paper, we obtain an approximate analytical expression of uninfected and infected cell population by solving the non-linear equations using Homotopy analysis method (HAM). Furthermore, the results are compared with the numerical simulation of the problem using Matlab program. The obtained results are valid for the whole solution domain.

KeywordsMathematical ModelingNon-Linear Differential EquationsNumerical SimulationHomotopy Analysis MethodTumor CellsOncolytic Viruses

D. H. Kirn and F. McCormick, “Replicating Viruses as Selective Cancer Therapeutics,” Molecular Medicine Today, Vol. 2, No. 12, 1996, pp. 519-527. doi:10.1016/S1357-4310(97)81456-6
K. A. Parato, D. Senger, P. A. Forsyth and J. C. Bell, “Recent Progress in the Battle between Oncolytic Viruses and Tumours,” Nature Reviews Cancer, Vol. 5, No. 12, 2005, pp. 965-976. doi:10.1038/nrc1750
F. McCormick, “Cancer-Specific Viruses and the Development of ONYX-015,” Cancer Biology and Therapy, Vol. 2, No. 4, 2003, pp. S157-S160.
H. Kasuya, S. Takeda, S. Nomoto and A. Nakao, “The Potential of Oncolytic Virus Therapy for Pancreatic Cancer,” Cancer Gene Therapy, Vol. 12, No. 9, 2005, pp. 725-736. doi:10.1038/sj.cgt.7700830
D. Kirn, T. Hermiston and F. McCormick, “ONYX-015: Clinical Data Are Encouraging,” Nature Medicine, Vol. 4, No. 12, 1998, pp. 1341-1342. doi:10.1038/3902
F. R. Khuri, J. Nemunaitis, I. Ganly, J. Arseneau, I. F. Tannock, L. Romel, M. Gore, J. Ironside, R. H. MacDougall, C. Heise, B. Randlev, A. M. Gillenwater, P. Bruso, S. B. Kaye, W. K. Hong and D. H. Kirn, “A Controlled Trial of Intratumoral ONYX-015, a SelectivelyReplicating Adenovirus, in Combination with Cisplatin and 5-Fluorouracil in Patients with Recurrent Head and Neck Cancer,” Nature Medicine, Vol. 6, No. 8, 2000, pp. 879-885. doi:10.1038/78638
J. Nemunaitis, F. Khuri, I. Ganly, J. Arseneau, M. Posner, E. Vokes, J. Kuhn, T. McCarty, S. Landers, A. Blackburn, L. Romel, B. Randlev, S. Kaye and D. Kirn, “Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients with Refractory Head and Neck Cancer,” Journal of Clinical Oncology, Vol. 19, No. 2, 2001, pp. 289-298.
A. C. Shah, D. Benos, G. Y. Gillespie and J. M. Markert, “Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas,” Journal of Neurooncology, Vol. 65, No. 3, 2003, pp. 203-226. doi:10.1023/B:NEON.0000003651.97832.6c
H. L. Kaufman, G. Deraffele, J. Mitcham, D. Moroziewicz, S. M. Cohen, K. S. Hurst-Wicker, K. Cheung, D. S. Lee, J. Divito, M. Voulo, J. Donovan, K. Dolan, K. Manson, D. Panicali, E. Wang, H. Horig and F. M. Mar-incola, “Targeting the Local Tumor Microenvironment with Vaccinia Virus Expressing B7.1 for the Treatment of Melanoma,” Journal of Clinical Investigation, Vol. 115, No. 7, 2005, pp. 1903-1912. doi:10.1172/JCI24624
T. Reid, R. Warren and D. Kirn, “Intravascular Adenoviral Agents in Cancer Patients: Lessons from Clinical Trials,” Cancer Gene Therapy, Vol. 9, No. 12, 2002, pp. 979-986. doi:10.1038/sj.cgt.7700539

Menu

Menu

Menu

Non-Linear Mathematical Model of the Interaction between Tumor and Oncolytic Viruses

Abstract

References (23)